EUVIMEDOpdag EUVIMED
VergleichsstudieOpen access · CC BY-NC-ND 4.0

Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes

Jincheng Shen, Amara Sarwal, Ravinder Singh, Sydney E Hartsell, Guo Wei, McKenna Nevers, Jesse C Christensen, Augustine Takyi, Niharika Katkam, Catherine G Derington, Vikrant G Deshmukh, Robert E Boucher and 3 more

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16207 ↗

At a glance

Vergleichsstudie in Diabetes, Obesity and Metabolism, 2025. Written by Jincheng Shen and 14 co-authors. Institution: Division of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Insulin Glargine, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Cited 2 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCRR NIH HHS, NCATS NIH HHS, NIA NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

To compare the risk of all‐cause death and cardiovascular events in new users of insulin glargine, glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), particularly in subgroups defined by baseline haemoglobin A1C (HbA1C), body mass index (BMI) and estimated glomerular filtration rate (eGFR). Materials and Methods We conducted an active comparator, new user design study in a national cohort of 161 405 veterans with type 2 diabetes (T2D) on metformin and initiated insulin glargine ( n = 54 375), GLP‐1RA ( n = 22 145) or SGLT2i ( n = 84 885) between 1 January 2018 and 31 December 2021. Patients were followed until 31 March 2023. Inverse probability weighted Cox regression models were used for treatment comparisons on all‐cause deaths and cardiovascular events in the entire cohort and above subgroups.

Results

There were 20 788 cardiovascular events/414 414 person‐years and 15 268 all‐cause deaths/446 458 person‐years. Insulin glargine had a higher hazard of all‐cause death compared to GLP‐1RA (hazard ratio [HR] 1.57, 95% confidence interval [CI] 1.48–1.67) or SGLT2i (HR 1.55, 95% CI 1.48–1.61) in the entire cohort and across subgroups, especially in those with HbA1C levels

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Insulin GlargineSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleFemaleMiddle AgedVeteransAgedGlycated HemoglobinCardiovascular DiseasesMetforminTreatment Outcome

Author keywords

GLP‐1SGLT2 inhibitorcardiovascular diseasedatabase researchinsulin therapytype 2 diabetes

Substances

Insulin GlargineSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinMetforminhemoglobin A1c protein, human

Authors and institutions

  • Division of Biostatistics, Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Cardio-Renal and Metabolism Center, University of Utah School of Medicine, Salt Lake City, Utah, USA.
  • Informatics Decision Enhancement and Surveillance (IDEAS) Center, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA.
  • Medical Service, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA.

ORCID profiles: Srinivasan Beddhu

Funding

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NIA NIH HHS
  • NIDDK NIH HHS
  • Veterans Health Administration Office of Rural Health
  • NHLBI NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute on Aging

Cite

APA

Shen, J., Sarwal, A., Singh, R., Hartsell, S. E., Wei, G., Nevers, M., Christensen, J. C., Takyi, A., Katkam, N., Derington, C. G., Deshmukh, V. G., Boucher, R. E., Drakos, S. G., Greene, T., & Beddhu, S. (2025). Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16207

Vancouver

Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, et al. Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16207

BibTeX
@article{Shen2025,
  author = {Shen, Jincheng and Sarwal, Amara and Singh, Ravinder and Hartsell, Sydney E and Wei, Guo and Nevers, McKenna and Christensen, Jesse C and Takyi, Augustine and Katkam, Niharika and Derington, Catherine G and Deshmukh, Vikrant G and Boucher, Robert E and Drakos, Stavros G and Greene, Tom and Beddhu, Srinivasan},
  title = {Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16207}
}
Start for free →